BPC-157 and the 503A Bulks List: What the July 2026 FDA Recommendation Changes

In late July 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend BPC-157 for the Section 503A Bulks List. If you work with this peptide, the vote is worth understanding — including what it does and does not change.

What the vote means

• Yes: PCAC recommended BPC-157 for the 503A Bulks List (along with KPV, TB-500, MOTS-c, Epitalon and Semax)
• No: this is not an FDA approval. The 503A list governs which bulk substances compounding pharmacies may use for patient-specific prescriptions
• Next: final inclusion requires formal rulemaking; the recommendation is advisory

What it does not change

BPC-157 remains an investigational compound with a preclinical-only evidence base. Most published data come from rodent and in vitro models of tissue repair:

• Angiogenesis (VEGF / nitric-oxide pathway)
• Tendon and ligament fibroblast activity
• Gastrointestinal mucosal protection and ulcer healing
• Nitric-oxide pathway modulation

No large-scale human efficacy trials have established clinical use, and the compound is not approved by any major regulatory authority. The research-grade supply channel is separate from pharmacy compounding.

BPC-157 at a glance

Property	Value
CAS	137525-51-0
Molecular formula	C62H98N16O22
Molecular weight	1419.5 g/mol
Form	Lyophilized powder (5 mg vial, 10 vials/box)
Purity	≥99.5% (HPLC-MS)
Solubility	Water
Storage	-20°C

Why the 503A interest matters for researchers

The regulatory attention is a demand signal — more institutions ask about documented sourcing when a compound moves through formal review. For procurement, the practical checklist is unchanged:

1. Batch-specific COA with HPLC-MS data
2. Lyophilized, sealed, stored cold
3. Clear research-only labeling

See the 503A overview and the peptide cliff analysis for the full regulatory picture. BPC-157 is also available in the BPC-157 + TB-500 blend.